SCHEMBL3201309

SCHEMBL3201309

FC(F)(F)Oc1ccc(-c2ccc3[nH]ccc3c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.60
BCR P11274 1/20 0.60
NPC1 O15118 1/20 0.57
CHRNB4 P30926 2/20 0.49
CHRNA3 P32297 2/20 0.49
CHRNA7 P36544 2/20 0.49
CHRNA10 Q9GZZ6 2/20 0.49
CHRNA9 Q9UGM1 2/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
CHRNB2 P17787 1/20 0.48
CHRNA4 P43681 1/20 0.48
CYP17A1 P05093 1/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
AHR P35869 2/20 0.44
PTGS2 P35354 1/20 0.44
JAK2 O60674 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3860188 0.87 GHSR (0.51) ABL1BCRNPC1CHRNB4CHRNA3
SCHEMBL1196876 0.86 ABL1 (0.52) ABL1BCRNPC1AHRCYP2A6
SCHEMBL28030810 0.86 NPC1 (0.57) ABL1BCRNPC1CHRNB4CHRNA3
SCHEMBL18002861 0.80 CYP2A6 (0.49) ABL1BCRNPC1CHRNB4CHRNA3
SCHEMBL5850255 0.78 NPC1 (0.79) NPC1CA12CA1CA2CA9
SCHEMBL7084999 0.78 NPC1 (0.62) NPC1CA12CA1CA2CA9
SCHEMBL7089083 0.78 NPC1 (0.62) NPC1CHRNB4CHRNA3CHRNA7CHRNA10
SCHEMBL12070110 0.77 AHR (0.58) NPC1CHRNB4CHRNA3CHRNA7CHRNA10
SCHEMBL3425763 0.77 ABL1 (1.00) ABL1BCR
SCHEMBL844827 0.77 PIM3 (0.54) ABL1BCRJAK2PRKD3MARK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674818-B2 Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH LLC (US) 2010-03-09 US disclosed
EP-1569901-B1 ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH CORP (US) 2008-10-15 EP disclosed
US-7348351-B2 Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH (US) 2008-03-25 US disclosed
US-20070259922-A1 Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH (US) 2007-11-08 US disclosed
US-7259182-B2 Deep vein thrombosis, noninsulin dependent diabetes, atherosclerosis, and pulmonary fibrosis treatment; cardiovascular and brain disorders WYETH (US) 2007-08-21 US disclosed
EP-1569899-B1 SUBSTITUTED 3-ALKYL- AND 3-ARYLALKYL-1H-INDOL-1-YL-ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH CORP (US) 2006-06-28 EP disclosed
CN-1723198-A Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH CORP (US) 2006-01-18 CN disclosed
EP-1569901-A2 ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) Wyeth (US) 2005-09-07 EP disclosed
EP-1569899-A2 SUBSTITUTED 3-ALKYL AND 3-ARYLALKYL i 1H /i -INDOL-1-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) Wyeth (US) 2005-09-07 EP disclosed
US-20040138283-A1 Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH (US) 2004-07-15 US disclosed
WO-2004052853-A2 SUBSTITUTED 3-ALKYL AND 3-ARYLALKYL 1H-INDOL-1-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2004-06-24 WO disclosed
WO-2004052854-A2 ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED 1H-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2004-06-24 WO disclosed
US-20040116488-A1 Substituted 3-alkyl and 3-arylalkyl 1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH 2004-06-17 US disclosed
US-20030203959-A1 Novel modulators of potassium channels 4SC AG (DE) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203959-A1 Novel modulators of potassium channels HCN3, KCNN3, KCNN1 ABL1 3070/4885BCR 2549/4885NPC1 487/4885
US-20040138283-A1 Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) SERPINE1, PLAT, SERPINC1 ABL1 851/4885BCR 1541/4885NPC1 2011/4885
US-20070259922-A1 Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) SERPINE1, SERPINC1, PLAT ABL1 953/4885BCR 1636/4885NPC1 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.